Table 2.
Participant demographics
|
Tuberculosis* |
Controls |
Total | ||||||
|---|---|---|---|---|---|---|---|---|
| Train | Test | Total | Train | Test | Total | |||
| Total number of patients | 102 | 77 | 179 | 91 | 79 | 170 | 349 | |
| Mean (range) age in years | 31 (16–86) | 33 (19–84) | 32 (16–86) | 44 (16–88) | 46 (14–84) | 45 (16–84) | 38 (14–88) | |
| Sex (male:female) | 65:37 | 47:30 | 112:67 | 52:39 | 42:37 | 94:76 | 206:143 | |
| Ethnic origin | ||||||||
| Sub-Saharan African | 81 (79%) | 60 (78%) | 141 (79%) | 29 (32%) | 29 (37%) | 58 (34%) | 199 | |
| African, not specified | 3 (3%) | 1 (1%) | 4 (2%) | 5 (6%) | 4 (5%) | 9 (5%) | 13 | |
| Asian | 13 (13%) | 9 (12%) | 22 (12%) | 6 (7%) | 3 (4%) | 9 (5%) | 31 | |
| White | 5 (5%) | 7 (9%) | 12 (7%) | 49(54%) | 39 (49%) | 88 (51%) | 100 | |
| Not recorded | .. | .. | .. | 2 (2%) | 4 (5%) | 6 (4%) | 6 | |
| Collection site | ||||||||
| Sub-Saharan Africa | 81 (79%) | 60 (78%) | 141 (79%) | 21 (23%) | 19 (24%) | 40 (24%) | 181 | |
| UK | 21 (21%) | 17 (22%) | 38 (21%) | 70 (77%) | 60 (76%) | 130 (76%) | 168 | |
| HIV serology | ||||||||
| HIV positive† | 35 (34%) | 24 (31%) | 59 (33%) | 2 (2%) | 3 (4%) | 5 (3%) | 64 | |
| CD4 count ≥200×106 per mL | 19 | 13 | 32 | .. | .. | .. | .. | |
| CD4 count <200×106 per mL | 15 | 11 | 26 | .. | .. | .. | .. | |
| HIV negative | 60 (59%) | 45 (58%) | 105 (59%) | 12 (13%) | 8 (10%) | 20 (12%) | 125 | |
| Not determined | 7 (7%) | 8 (10%) | 15 (8%) | 77 (85%) | 68 (86%) | 145 (85%) | 160 | |
Percentages refer to proportion of patients in the training and testing set for each demographic category.
*
12 patients with tuberculosis had received 1–7 days of chemotherapy at time of recruitment.
†
CD4 counts were available for HIV-seropositive patients; no value was available for six seropositive patients.